Skip to main content
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. — Investor Relations & Filings

Ticker · PCRX ISIN · US6951271005 LEI · 549300P56LERYBDHCF69 US Manufacturing
Open in API
Filings indexed 1,217 across all filing types
Latest filing 2021-12-07 Earnings Release
Country US United States of America
Listing US PCRX

About Pacira BioSciences, Inc.

https://www.pacira.com/

Pacira BioSciences, Inc. is a pharmaceutical company that develops, commercializes, and manufactures non-opioid pain management and regenerative health solutions. The company's mission is to provide alternatives to opioids by delivering innovative, precise, and targeted therapies. Its products and research pipeline address a diverse range of needs, including postsurgical, chronic, and musculoskeletal pain. Pacira is also focused on developing advanced solutions, including gene therapy, to address unmet needs in pain management.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and refers to a press release announcing preliminary unaudited revenue for a recent month. The document does not contain detailed financial statements or comprehensive financial analysis but rather a brief announcement of preliminary financial results. The document length is 3392 characters, which is relatively short and consistent with a current report or earnings release announcement. However, since it is a Form 8-K announcing preliminary revenue results and includes a press release, it aligns best with an Earnings Release (ER) category, which covers initial announcements of quarterly or periodical financial results with key highlights only. It is not a full quarterly or annual report, nor a regulatory filing of certifications or other types. Therefore, the classification is Earnings Release (ER).
2021-12-07 English
FORM 4 SUBMISSION
Director's Dealing
2021-11-24 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major corporate events. The content describes the entry into a material definitive agreement (a merger agreement), the completion of an acquisition (merger of Flexion Therapeutics into Pacira BioSciences), details about contingent value rights (CVRs), tender offer results, and other merger-related transactions. It also references exhibits such as the merger agreement and a press release. There are no full financial statements or detailed financial performance data included in the text, only descriptions of the transaction and related agreements. This type of filing is best classified as a Regulatory Filing (RNS) because it is a current report announcing a material event rather than a full annual or quarterly report, earnings release, or merger proxy statement. The document length and detail confirm it is not a brief announcement but a formal regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-11-19 English
SC TO-T/A Filing
M&A Activity Classification · 100% confidence The document is a Schedule TO filing with the SEC, specifically an Amendment No. 4 to a Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934. It details the terms and results of a tender offer by Oyster Acquisition Company Inc. to purchase shares of Flexion Therapeutics, Inc., including the consummation of a merger and related transaction details. The document includes legal and transaction-specific information about the tender offer and merger, including exhibits such as the Offer to Purchase, Letter of Transmittal, and press releases. This type of filing is related to merger and acquisition activity and tender offers, which falls under the category of M&A Activity (TAR). The document is not a general regulatory filing, nor is it a proxy statement or a merger proxy (which would be MA). It is specifically a Schedule TO amendment related to a tender offer, which is classified as M&A Activity (TAR). The document length and content confirm it is a substantive filing, not just an announcement or certification.
2021-11-19 English
FORM 4 SUBMISSION
Director's Dealing
2021-11-18 English
SC TO-T/A Filing
M&A Activity Classification · 100% confidence The document is a Schedule TO filing with the SEC, specifically an Amendment No. 3 to a Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934. It relates to a tender offer by Oyster Acquisition Company Inc., a subsidiary of Pacira BioSciences, Inc., to purchase shares of Flexion Therapeutics, Inc. The document includes detailed information about the tender offer, legal and regulatory compliance, and exhibits such as the Offer to Purchase and related agreements. This type of filing is directly related to a takeover bid or merger transaction. According to the filing definitions, documents related to merger proposals or takeover bids fall under the category 'M&A Activity' with the code TAR. The document length is substantial (over 11,000 characters) and contains substantive content, not just an announcement or certification, so it is not an RPA or RNS. Therefore, the correct classification is TAR with high confidence.
2021-11-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.